Home



ZADAXIN
(thymosin alpha 1)




ZADAXIN
Bibliography &
Presentations




Medical
Conferences




Contact



Site Map



International
Language Support


   
ZADAXIN Bibliography, Presentations and Selected Clinical Abstracts

ZADAXIN Bibliography
ZADAXIN Presentations

ZADAXIN: (Thymalfasin/Thymosin alpha 1):
Monotherapy and Combination Therapy of Hepatitis B

APASL 2006, Manila, Philippines March 6th, 2006

Therapeutic Strategies for Liver Disease
Hepatitis B, Hepatitis C, and Hepatocellular Carcinoma
Treatment Regimens Using Thymalfasin, An Immune System Enhancer
Symposium – EASL 2006, Thursday, April 27th – Austria Center Vienna

Treatment of HCV Non-Responders
APASL 2005 Bali, Indonesia August 21st, 2005

The Role of Thymosin Alpha-1 in the Treatment of
Hepatitis B Infection

APASL 2005 Bali, Indonesia August 20th, 2005

Therapeutic Strategies for Difficult to Treat HBV & HCV Patient Groups:
Treatment Regimens using Thymalfasin, An Immune System Enhancer
Symposium - EASL 2005, Thursday, April 25th – Palais de Congres

Therapeutic Strategies for Treatment Resistant HBV/HCV:    
Treatment Regimens with Thymosin a-1, An Immune System Enhancer (ISE)

APASL 2004 Satellite Symposium

Therapeutic Strategies for Treatment Resistant HBV / HCV
Treatment Regimens with Thymalfasin, An Immune System Enhancer (ISE)
Thursday, 15 April 2004 - Internationales Congress Centrum, Berlin

Therapeutic Strategies for HBV / HCV Relapse: The Role of Thymalfasin
Satellite Symposium – EASL 2003, Geneva, Switzerland
Le Cervin Hall, 13:00 – 14:00

Thymalfasin: Advances in Immunomodulatory Therapy of Liver Disease
Symposium – EASL 2002, Monday, April 15th – Palacio De Congresos de Madrid

 

Selected Clinical Abstracts
Thymalfasin (Thymosin Alpha 1) With Trans Arterial Chemoembolization (TACE) in the Treatment of Adult Patients with Unresectable Hepatocellular Carcinoma: A Phase II Trial

Gish R. Rustgi V, Nelson D, Gordon S, Rudolph A
Presented at: Shanghai-Hong Kong International Liver Congress 2006

Efficacy of Triple Therapy with Thymalfasin (Thymosin Alpha 1) In Combination with Peginterferon Alfa-2A and Ribavirin for the Treatment of HCV Nonresponders

Jorge L. Poo, Francisco Sanchez-Avila, Nahum Mendez, Misael Uribe
Presented at: The European Association for the Study of Liver (EASL); April 14-18, 2004, Berlin, Germany

A Pilot Trial of Thymalfasin (Thymosin Alpha-1) in Combination With Peginterferon ALPHA-2A (PEG-IFN2A) and Ribavirin in HCV Non-Responders: 12-Week Interim Results

54th Annual Meeting of The American Association for the Study of Liver Diseases, October 24 - 28, 2003, Boston, Massachusetts, John B. Hynes Convention Center

Jorge L. Poo, Cif-Biotec, Mexico City, Mexico; Xochil Garcia, Hospital Lopez Mateos ISSSTE, Mexico City, Mexico; Eduardo B. Martins, SciClone Pharmaceuticals, San Mateo, CA; David Kershenobich, INCMN Salvador Zubiran, Mexico City, Mexico.

Thymalfasin - Advances in Immunomodulatory Therapy of Liver Disease

Publications presented at: Madrid, Spain; 2002 Symposium

HCV RNA and Immunological Responses to Thymalfasin in Combination With Peginterferon ALFA-2A in HCV Non-Responders: A 12-Week Kinetic Study

Rehan Iftikar, Adrian Di Bisceglie, Saint Louis University School of Medicine, St. Louis, Mo; Paul J. Pockros,
Scripps Clinic, La Jolla, CA; Vinod K. Rustgi, Georgetown University Medical Center & Metropolitan Liver Diseases,
Fairfax, Va; Marisa Schulman, Metropolitan Liver Diseases, Fairfax, Va; Eduardo B. Martins, SciClone Pharmaceuticals, Inc., San Mateo, Ca

HCC Patients Treated with TACE Combined with Thymalfasin – One Year Follow up

Dr. ZS Li, Division of Gastroenterology, Shanghai Hospital, the second Military Medical University, Shanghai, PRC., Shanghai International Oncology Conference, April 2001




  Home | Zadaxin | Scientific Papers | Conferences | Contact | Site Map
Copyright © 2003-2004 SciClone Pharmaceuticals International